GIP and sleep apnea syndrome: A GLP-1 RA with GIP (glucose-dependent insulinotropic polypeptide), tirzepatide, has been approved for moderate-to-severe OSA with obesity due to its efficacy in reducing apnea severity, achieving sleep apnea resolution (AHI < 5 or AHI 5–14 without excessive daytime sleepiness) and weight reduction [69].